Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 1/20 | 0.53 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 7/20 | 0.50 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.45 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.45 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.45 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10594828 | 0.82 | CNR2 (0.46) | ALDH1A1MAPTCA2CA1 | |
| SCHEMBL186305 | 0.82 | CA2 (0.61) | PLA2G10PLA2G2APARP10CYP17A1PARP4 | |
| SCHEMBL2633786 | 0.80 | PLA2G10 (0.55) | PLA2G10PLA2G2APARP10CYP17A1PARP4 | |
| SCHEMBL2861358 | 0.80 | PLA2G10 (0.55) | PLA2G10PLA2G2APARP10CYP17A1PARP4 | |
| SCHEMBL8867699 | 0.80 | PLA2G10 (0.55) | PLA2G10PLA2G2APARP10CYP17A1PARP4 | |
| SCHEMBL3962189 | 0.80 | CA1 (0.43) | KMT2AALDH1A1POLBMAPTTSHR | |
| SCHEMBL632555 | 0.80 | ALDH1A1 (0.56) | KMT2AALDH1A1POLBMAPTTSHR | |
| SCHEMBL5536952 | 0.78 | PLA2G10 (0.53) | PLA2G10PLA2G2APARP10CYP17A1PARP4 | |
| SCHEMBL12970843 | 0.78 | PLA2G10 (0.53) | PLA2G10PLA2G2APARP10CYP17A1PARP4 | |
| SCHEMBL2658380 | 0.78 | KMT2A (0.61) | KMT2AMAPTHSD17B10L3MBTL1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049620-A1 | Cyclic tertiary amine compound | SANKYO COMPANY, LIMITED (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1632488-A1 | CYCLIC TERTIARY AMINE COMPOUND | Sankyo Company, Limited (JP) | 2006-03-08 | — | — | EP | disclosed |
| EP-0912586-B1 | FUNCTIONALIZED FERROCENYLDIPHOSPHINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE | SYNGENTA PARTICIPATIONS AG (CH) | 2002-01-16 | — | — | EP | disclosed |
| US-6169192-B1 | LIGANDS FOR TRANSITION METAL COMPLEXES SUITABLE FOR ENANTIOSELECTIVE HYDROGENATION OF ORGANIC DOUBLE OR TRIPLE BONDS | NOVARTIS AG (CH) | 2001-01-02 | — | — | US | disclosed |
| EP-0912586-A1 | FUNCTIONALIZED FERROCENYLDIPHOSPHINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE | Novartis AG (CH) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998001457-A1 | FUNCTIONALIZED FERROCENYLDIPHOSPHINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE | NOVARTIS AG (CH) | 1998-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049620-A1 | Cyclic tertiary amine compound | MYD88, IL5, BRD4 | PLA2G10 4115/4885PLA2G2A 4413/4885PARP10 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.